176 related articles for article (PubMed ID: 23471717)
1. CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from central south China.
Huang FM; Chen HC; Khan MA; Yang FL; Wan XX; Xu AH; Ou-yang FD; Zhang DZ
Med Oncol; 2013 Jun; 30(2):521. PubMed ID: 23471717
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility.
Luo YP; Chen HC; Khan MA; Chen FZ; Wan XX; Tan B; Ou-Yang FD; Zhang DZ
Tumour Biol; 2011 Feb; 32(1):215-22. PubMed ID: 20878561
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.
Islam MS; Ahmed MU; Sayeed MS; Maruf AA; Mostofa AG; Hussain SM; Kabir Y; Daly AK; Hasnat A
Clin Chim Acta; 2013 Feb; 416():11-9. PubMed ID: 23178447
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
Chen HC; Hu WX; Liu QX; Li WK; Chen FZ; Rao ZZ; Liu XF; Luo YP; Cao YF
Eur J Cancer Prev; 2008 Jun; 17(3):251-8. PubMed ID: 18414197
[TBL] [Abstract][Full Text] [Related]
5. [Association between genetic polymorphism and lung cancer risk].
Ariyoshi N; Kitada M; Kamataki T
Nihon Rinsho; 2002 May; 60 Suppl 5():46-9. PubMed ID: 12101715
[No Abstract] [Full Text] [Related]
6. GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels.
Butkiewicz D; Cole KJ; Phillips DH; Harris CC; Chorazy M
Eur J Cancer Prev; 1999 Aug; 8(4):315-23. PubMed ID: 10493307
[TBL] [Abstract][Full Text] [Related]
7. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
8. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population.
Sobti RC; Sharma S; Joshi A; Jindal SK; Janmeja A
Biomarkers; 2003; 8(5):415-28. PubMed ID: 14602525
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.
Li W; Yue W; Zhang L; Zhao X; Ma L; Yang X; Zhang C; Wang Y; Gu M
Lung; 2012 Feb; 190(1):91-8. PubMed ID: 22109568
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients.
Khlifi R; Chakroun A; Hamza-Chaffai A; Rebai A
Mol Biol Rep; 2014; 41(4):2591-600. PubMed ID: 24449363
[TBL] [Abstract][Full Text] [Related]
12. CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia.
Idris HME; Khalil HB; Mills J; Elderdery AY
Curr Cancer Drug Targets; 2020; 20(9):675-680. PubMed ID: 32418524
[TBL] [Abstract][Full Text] [Related]
13. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides.
Singh S; Kumar V; Vashisht K; Singh P; Banerjee BD; Rautela RS; Grover SS; Rawat DS; Pasha ST; Jain SK; Rai A
Toxicol Appl Pharmacol; 2011 Nov; 257(1):84-92. PubMed ID: 21907728
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile.
Muñoz S; Vollrath V; Vallejos MP; Miquel JF; Covarrubias C; Raddatz A; Chianale J
Pharmacogenetics; 1998 Aug; 8(4):343-51. PubMed ID: 9731721
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in CYP1A1, CYP2D6, UGT1A6, UGT1A7, and SULT1A1 genes and correlation with benzene exposure in a Chinese occupational population.
Gu SY; Zhang ZB; Wan JX; Jin XP; Xia ZL
J Toxicol Environ Health A; 2007 Jun; 70(11):916-24. PubMed ID: 17479406
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between the genetic polymorphisms of phase I and II drug-metabolizing enzymes, as well as the outcome of chemotherapy in advanced non-small cell lung cancer].
Li W; Yue W; Yang X; Zhang C; Wang Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):858-64. PubMed ID: 22104220
[TBL] [Abstract][Full Text] [Related]
17. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
Yokoi T; Kamataki T
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
[TBL] [Abstract][Full Text] [Related]
18. CYP1A1 and CYP2D6 gene polymorphisms in Israeli Jewish women with cervical cancer.
Gutman G; Morad T; Peleg B; Peretz C; Bar-Am A; Safra T; Grisaru D
Int J Gynecol Cancer; 2009 Nov; 19(8):1300-2. PubMed ID: 20009880
[TBL] [Abstract][Full Text] [Related]
19. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
20. [Study on the relationship between polymorphisms of Cyp1A1, GSTM1, GSTT1 genes and the susceptibility to acute leukemia in the general population of Hunan province].
Liu QX; Chen HC; Liu XF; Cao YF; Zhang J; Liu J
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Dec; 26(12):975-9. PubMed ID: 16676594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
